- Home
- GH vs DVA Comparison
GH vs DVA Comparison
Compare GH & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GH | DVA |
|---|---|---|
| Founded | 2011 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.3B | 15.1B |
| IPO Year | 2018 | 2003 |
Fundamental Metrics
Financial Performance| Metric | GH | DVA |
|---|---|---|
| Price | $159.68 | $233.56 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 19 | 4 |
| Target Price | $119.79 | ★ $156.75 |
| AVG Volume (30 Days) | ★ 2.8M | 732.3K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 6.74 | N/A |
| EPS | N/A | ★ 2.87 |
| Revenue | $982,021,000.00 | ★ $13,643,069,000.00 |
| Revenue This Year | $33.30 | $3.85 |
| Revenue Next Year | $28.27 | $3.07 |
| P/E Ratio | ★ N/A | $79.91 |
| Revenue Growth | ★ 32.88 | 6.46 |
| 52 Week Low | $40.36 | $101.00 |
| 52 Week High | $174.08 | $239.64 |
Technical Indicators
Market Signals| Indicator | GH | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 62.75 | 74.75 |
| Support Level | $82.81 | $145.58 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 8.29 | 6.30 |
| MACD | 0.34 | 0.51 |
| Stochastic Oscillator | 69.86 | 80.93 |
Price Performance
Historical ComparisonAbout GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About DVA DaVita Inc.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.